Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
STOXIL is a small-molecule ophthalmic solution approved in 1964 for viral eye infections, likely containing idoxuridine or a related antiviral nucleoside analog. The drug is administered as topical eye drops and works by inhibiting viral DNA synthesis in ocular tissues.
Product is in late maturity with moderate competitive pressure (30%), indicating a defensive/maintenance-focused commercial strategy with limited team expansion opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
STOXIL offers limited career growth due to approaching LOE and minimal linked job openings; roles focus on defending market share and managing stakeholder relationships rather than launching new initiatives. This assignment is suitable for professionals seeking stable, lower-pressure positions in specialty ophthalmology.
Worked on STOXIL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.